Boehringer Ingelheim and ImmunoGen Sign Exclusive License Agreement ImmunoGen, Inc develops innovative biopharmaceuticals, primarily for cancer treatment The Company has created potent tumor-activated prodrugs, consisting of drugs coupled to monoclonal antibodies, for delivery to and destruction of cancer cells
SEC Filing | ImmunoGen, Inc. 2 Issuer Name and Ticker or Trading Symbol ImmunoGen, Inc [ IMGN ] 5 Relationship of Reporting Person (s) to Issuer (Check all applicable) X Director 10% Owner Officer (give title below) Other (specify below)
First Clinical Data Presented with IMGN853, ImmunoGen, Inc. s Potential . . . WALTHAM, Mass --(BUSINESS WIRE)-- ImmunoGen, Inc (Nasdaq: IMGN), a biotechnology company that develops anticancer therapeutics using its Targeted Antibody Payload (TAP) ADC technology, today announced the presentation of the first clinical data with the Company's IMGN853 product candidate
ImmunoGen BioInvent Sign Antibody Manufacturing Agreement ImmunoGen, Inc develops innovative biopharmaceuticals, primarily for cancer treatment The Company has created potent tumor-activated prodrugs (TAPs), consisting of small molecular, cytotoxic drugs coupled to monoclonal antibodies, for delivery to and destruction of cancer cells
ImmunoGen, Inc. Regains Development and Commercialization Rights for . . . ImmunoGen holds the Investigational New Drug application (IND) for cantuzumab mertansine and has rights to all clinical data generated in the Phase I studies The two companies will work together to ensure a smooth transition of all study data
ImmunoGen, Inc. Announces Exercise of Over-allotment Option ImmunoGen, Inc develops targeted anticancer therapeutics using its expertise in cancer biology, monoclonal antibodies and the creation and linkage of potent cancer-cell killing agents (CKAs) to such antibodies
ImmunoGen Announces Favorable Preliminary Phase I II Data on huC242-DM1 . . . ImmunoGen, Inc develops innovative biopharmaceuticals, primarily for cancer treatment The Company has created potent tumor-activated prodrugs, consisting of drugs coupled to monoclonal antibodies for delivery to and destruction of cancer cells